Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13

Benzinga · 19h ago
Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.